New study aims to match breast cancer treatment to genetic risk scores
NCT ID NCT06650748
First seen Mar 31, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study looks at whether adding a targeted drug (CDK4/6 inhibitor) to standard hormone therapy before surgery can improve outcomes for women with a specific type of early-stage breast cancer (HR+/HER2-). Researchers will use a genetic test and early changes in a cell growth marker (Ki-67) to decide who gets the added drug. About 100 women aged 18-70 will participate to see if this personalized approach leads to better tumor shrinkage or complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.